CLINICAL_TRIALS
trial_result
· 2017-03-03
Clinical Trial Update: A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma [Phase 2]
Summary
A Phase 2 study evaluating the combination of pertuzumab and erlotinib for refractory pancreatic cancer was terminated, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: George Albert Fisher | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-03